Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.

The results of preclinical and clinical studies indicate enhanced antineoplastic activity of topotecan (SKF 104864-A) when administered as a chronic treatment. We determined the apparent bioavailability and pharmacokinetics of topotecan administered orally to 12 patients with solid tumours in a two-...

Descripción completa

Detalles Bibliográficos
Autores principales: Schellens, J. H., Creemers, G. J., Beijnen, J. H., Rosing, H., de Boer-Dennert, M., McDonald, M., Davies, B., Verweij, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074523/
https://www.ncbi.nlm.nih.gov/pubmed/8630291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074523/
https://www.ncbi.nlm.nih.gov/pubmed/8630291

Ejemplares similares